<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959764</url>
  </required_header>
  <id_info>
    <org_study_id>UGL-OR0801</org_study_id>
    <secondary_id>2008-003322-42</secondary_id>
    <nct_id>NCT00959764</nct_id>
  </id_info>
  <brief_title>A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women</brief_title>
  <acronym>ORACAL</acronym>
  <official_title>A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48-Week, Study of Oral Recombinant Salmon Calcitonin (rsCT) Compared to Salmon Calcitonin (sCT) Nasal Spray in Postmenopausal Osteoporotic Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tarsa Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tarsa Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and tolerability of two
      medications, calcitonin nasal spray and a tablet containing calcitonin, in postmenopausal
      women with osteoporosis. Osteoporosis is the term used to describe a large group of diseases,
      which are characterized by loss of bone density, which makes the bones weaker. Osteoporosis
      often occurs in postmenopausal women.

      Calcitonin is a hormone found in the human body. Together with other substances, it regulates
      the concentration of calcium in the blood and inhibits the natural resorption of bone. Both
      medications in this study contain salmon calcitonin (sCT), because this form of calcitonin is
      more active than human calcitonin when used as a medicine.

      The calcitonin Nasal Spray used in this study is registered and available to doctors in
      United States for the treatment of osteoporosis. The medication being tested in this study is
      an oral tablet form of salmon calcitonin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, double-dummy, multiple dose, placebo-controlled,
      parallel group, 48- week, Phase III study. Women age 45 and over who were postmenopausal and
      had a diagnosis of osteoporosis were eligible for the study and were randomly allocated to
      one of three treatment groups; placebo tablets, oral rsCT tablets or calcitonin nasal spray.
      Each patient was given a treatment kit, which contained the study medication to which she had
      been assigned and a placebo of the treatment to which she was not assigned, or placebo nasal
      and oral preparations, as well as the required dietary supplements (calcium and vitamin D
      tablets). The study medication and supplements were self-administered at home. It was
      anticipated that approximately 545 patients would participate in the study.

      EFFICACY: Bone Mineral Density (BMD) was recorded at Screening, Week 24, and Week 48. CTx-1
      and N-telopeptide of collagen 1 (NTx-1), biochemical markers of bone resorption and total
      Procollagen type 1 N-terminal propeptide (P1NP),a marker of bone formation, were assessed at
      Week 0, Week 24, and Week 48. SAFETY: Adverse events were assessed at the clinic at Weeks 0,
      12, 24, 36 and 48, and by interim phone calls at Weeks 4, 8, 16, 20, 28, 32, 40, 44, and 52.
      At Screening, Week 12, and Week 48, a physical examination, including nasal exam, was
      performed and specimens for safety laboratory analysis (clinical chemistry, hematology, and
      urinalysis) were collected. Sera for immunogenicity evaluations were collected at Baseline,
      Week 12, and Week 48.

      EFFICACY: The primary comparison of interest was the percent change from baseline to 48 weeks
      in axial lumbar spine (L1 to L4) corrected BMD comparing the rsCT oral tablet group and the
      calcitonin nasal spray group. The model included the factors of the covariate (baseline BMD),
      treatment group, and center. The hypothesis to be tested was performed to examine the
      non-inferiority of the oral tablet group to the nasal spray group with respect to the percent
      change in axial lumbar L1-L4 spine corrected BMD. Specifically, the null hypothesis to be
      tested was: [Mean(oral) - Mean(placebo)] - 0.5 x [Mean(nasal) - Mean(placebo)] &lt; 0 The
      alternative hypothesis was that the above expression was &gt; 0, which implied that the oral
      tablet group was non-inferior to nasal spray group. The primary analysis of interest employed
      the modified intent-to-treat population.

      SAFETY: Adverse events were summarized descriptively. Mean vital signs and clinical
      laboratory test results in each treatment group were compared using a one-way analysis of
      variance. Additionally, shift tables were prepared for each laboratory variable.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density (BMD) of Axial Lumbar Spine</measure>
    <time_frame>48 weeks</time_frame>
    <description>Bone Mineral Density is measured by Dual-Energy X-ray Absorptiometry (DXA) body scans. Two scans were taken for each timepoint(baseline, week 24 and week 48) and the mean of the two values was entered. The primary outcome timepoint was 48 weeks, but if a patient did not complete the full study, then the 24 week BMD value was used as Last Observation Carried Forward. The percentage change from the baseline value, set as 0%, was recorded as the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma C-terminal Telopeptide of Collagen 1 (CTx-1)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in plasma CTx-1 at 24 and 48 weeks. CTx-1 is an accepted plasma biomarker as evidence of an effect on bone resorption and the effect of oral calcitonin was compared to that of intranasal calcitonin, both vs placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma CTx-1 From Baseline</measure>
    <time_frame>48 weeks</time_frame>
    <description>Percent change from baseline of plasma CTx-1 at end of study=48 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">565</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Oral calcitonin and placebo nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Oral calcitonin tablet (along with placebo intranasal spray)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal calcitonin &amp; oral placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Commercially available, active comparator, intranasal calcitonin-salmon (plus matching oral placebo tablet).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: tablet &amp; intranasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Both oral matching placebo tablets and matching intranasal placebo spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Calcitonin Tablets</intervention_name>
    <description>Oral Calcitonin tablets along with matching placebo intranasal spray</description>
    <arm_group_label>Oral calcitonin and placebo nasal spray</arm_group_label>
    <other_name>rsCT tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Calcitonin</intervention_name>
    <description>Intranasal Calcitonin Spray</description>
    <arm_group_label>Intranasal calcitonin &amp; oral placebo</arm_group_label>
    <other_name>Miacalcin and Miacalcic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets and placebo intranasal spray</intervention_name>
    <description>Oral Placebo Tablets/Intranasal placebo spray</description>
    <arm_group_label>Placebo: tablet &amp; intranasal spray</arm_group_label>
    <other_name>Matching placebos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and age 45 or over.

          -  Must have undergone the onset of spontaneous or surgical menopause. Spontaneous
             menopause is defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous
             amenorrhea with serum Follicle Stimulating Hormone (FSH) levels &gt;40
             milli-international units (mIU)/milliliter (mL) or 6 weeks post-surgical bilateral
             oophorectomy with or without hysterectomy.

          -  Diagnosis of osteoporosis on the basis of an axial lumbar spine, femoral neck or total
             hip BMD which is below the mean for premenopausal women by a magnitude of at least 2.5
             SD or 2.0 SD, if there is a documented history of a vertebral fragility fracture.

          -  Must have at least three contiguous lumbar vertebrae (L1-L4) that are evaluable by DXA
             for BMD that is, without fracture or significant degenerative disease, as determined
             by Bio-Imaging Technologies, Inc.

          -  No clinically significant abnormal findings in the medical history, physical exam or
             nasal exam.

          -  No clinically significant abnormal laboratory values at the screening assessment.

        Exclusion Criteria:

          -  History of severe allergic disease.

          -  History of metabolic and other bone diseases, including osteogenesis imperfecta,
             osteomalacia, and Paget's disease.

          -  Vitamin D insufficiency defined as a 25 hydroxyvitamin D level &lt;20 ng/mL.

          -  Use of any intravenous bisphosphonate in the past 24 months, or &gt;2 doses of
             intravenous bisphosphonate ever.

          -  Use of oral bisphosphonate before randomization, including investigational
             bisphosphonates, unless: 1) less than 6 months of treatment and off for 6 months, or
             2) 6 to 12 months of treatment and off for 2 years, or 3) More than 12 months of
             treatment and off for 5 years

          -  Use of denosumab, fluoride, or strontium, ever.

          -  Use of parathyroid hormone analogs or other bone metabolic agents within 1 year
             preceding randomization.

          -  Any condition or disease that may interfere with the ability to have a DXA scan or to
             evaluate a DXA scan, for example, severe osteoarthritis of the spine, spinal fusion,
             pedicle screws, history of vertebroplasty, or degenerative disease that results in
             insufficient number of evaluable lumbar vertebrae, or more than 1 lumbar vertebral
             fracture in L1 through L4. (More than 4 vertebral fractures in T4 through L4;
             Bilateral hip replacements)

          -  Use of anabolic steroids or androgens within 6 months preceding randomization.

          -  Use of Vitamin D metabolites and analogs, (e.g., calcitriol) within 3 months preceding
             randomization). Note: Vitamin D supplementation is not exclusionary.

          -  Use of estrogen or estrogen-related drugs, for example, tamoxifen, tibolone, or
             raloxifene within 3 months preceding randomization.

          -  Use of coumadin within 4 weeks preceding randomization or heparin within 1 week
             preceding randomization.

          -  Chronic systemic treatment with glucocorticoids, hormone replacement therapy,
             calcitonin or any other medication within the previous three months which, in the
             opinion of the Investigator, would interfere with the study.

          -  Clinically relevant abnormal history, physical findings or laboratory values at the
             pre-study screening assessment that could interfere with the objectives of the study
             or the safety of the patient.

          -  Presence of acute or chronic illness or history of chronic illness which, in the
             judgment of the Investigator, makes participation in the study medically
             inappropriate.

          -  Uncontrolled hypertension, significant gastrointestinal abnormalities, uncontrolled
             diabetes mellitus, significant coronary heart disease, any psychotic mental illness,
             chronic allergic rhinitis, asthma, uncorrected endocrine dysfunction, or significantly
             impaired hepatic, respiratory or renal function.

          -  History of drug or alcohol abuse, or intake of more than 30 units of alcohol weekly.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Krause, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Tarsa Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Associates of N. AL, P.C.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Institute for Bone Health, Inc.</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Health Research Center/Bone Health Center of Bethesda</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>801 N. 30th Street, Suite 6718</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Clinical Research &amp; Osteoporosis</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bone Mineral Research Center</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Geriatrics &amp; Endocrinology/Medical Sciences Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Centre, &quot;Sveta Anna&quot; EOOD Sofia (Rheumatology Outpatient Office)</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Hungary Ltd</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus SCM Sp zoo</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centres SA (Pty) Ltd</name>
      <address>
        <city>Gauteng</city>
        <state>Pretoria</state>
        <zip>0184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Thames Valley Clinical Research Centre</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG2 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Midlands Clinical Research Centre</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Wales Clinical Research Centre</name>
      <address>
        <city>Llanishen</city>
        <state>Cardiff</state>
        <zip>CF14 5GJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Scotland Clinical Research Centre</name>
      <address>
        <city>Clydebank</city>
        <state>Glasgow</state>
        <zip>G81 2DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Merseyside Clinical Research Centre</name>
      <address>
        <city>Waterloo</city>
        <state>Liverpool</state>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Lancashire Clinical Research Centre</name>
      <address>
        <city>Chorley</city>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Manchester Clinical Research Centre</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS; Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012 Aug;27(8):1821-9. doi: 10.1002/jbmr.1602.</citation>
    <PMID>22437792</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2009</study_first_submitted>
  <study_first_submitted_qc>August 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2009</study_first_posted>
  <results_first_submitted>October 26, 2012</results_first_submitted>
  <results_first_submitted_qc>September 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2013</results_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from clinics in the USA,UK,Poland, Bulgaria, Hungary, and Republic of South Africa.</recruitment_details>
      <pre_assignment_details>Unequal randomization was used for the study, with patients being assigned after inclusion/exclusion criteria were met.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Calcitonin</title>
          <description>Patients who only received oral calcitonin as an active treatment</description>
        </group>
        <group group_id="P2">
          <title>Nasal Calcitonin</title>
          <description>Patients who only received nasal calcitonin as active treatment</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Patients who did not receive any active treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
                <participants group_id="P2" count="185"/>
                <participants group_id="P3" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Calcitonin</title>
          <description>Patients who only received oral calcitonin as an active treatment</description>
        </group>
        <group group_id="B2">
          <title>Nasal Calcitonin</title>
          <description>Patients who only received nasal calcitonin as active treatment</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Patients who did not receive any active treatment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="271"/>
            <count group_id="B2" value="185"/>
            <count group_id="B3" value="109"/>
            <count group_id="B4" value="565"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.5" spread="7.6"/>
                    <measurement group_id="B2" value="66.4" spread="7.0"/>
                    <measurement group_id="B3" value="66.5" spread="8.0"/>
                    <measurement group_id="B4" value="66.5" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Bone Mineral Density (BMD) of Axial Lumbar Spine</title>
        <description>Bone Mineral Density is measured by Dual-Energy X-ray Absorptiometry (DXA) body scans. Two scans were taken for each timepoint(baseline, week 24 and week 48) and the mean of the two values was entered. The primary outcome timepoint was 48 weeks, but if a patient did not complete the full study, then the 24 week BMD value was used as Last Observation Carried Forward. The percentage change from the baseline value, set as 0%, was recorded as the primary outcome measure.</description>
        <time_frame>48 weeks</time_frame>
        <population>Patients who were randomized, received treatment, and had at least one post-baseline BMD value measured at least 154 days after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Calcitonin</title>
            <description>Patients who were provided active oral calcitonin and placebo nasal medication in a blinded fashion.</description>
          </group>
          <group group_id="O2">
            <title>Nasal Calcitonin</title>
            <description>Patients who were provided active nasal calcitonin and placebo oral medication in a blinded fashion.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients who were provided nasal and oral placebo medication in a blinded fashion</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density (BMD) of Axial Lumbar Spine</title>
          <description>Bone Mineral Density is measured by Dual-Energy X-ray Absorptiometry (DXA) body scans. Two scans were taken for each timepoint(baseline, week 24 and week 48) and the mean of the two values was entered. The primary outcome timepoint was 48 weeks, but if a patient did not complete the full study, then the 24 week BMD value was used as Last Observation Carried Forward. The percentage change from the baseline value, set as 0%, was recorded as the primary outcome measure.</description>
          <population>Patients who were randomized, received treatment, and had at least one post-baseline BMD value measured at least 154 days after randomization.</population>
          <units>Percentage increase from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="3.17" lower_limit="-7.20" upper_limit="12.00"/>
                    <measurement group_id="O2" value="0.76" spread="2.91" lower_limit="-7.49" upper_limit="9.10"/>
                    <measurement group_id="O3" value="0.47" spread="3.21" lower_limit="-9.78" upper_limit="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The overall analysis across groups was an Analysis of Covariance where the study was powered to 80% with an assumption of a standard deviation of 2.5% and a two-sided 5% level of significance. For each treatment group, the BMD at 48 weeks was compared with the BMD at baseline and a % increase was calculated (baseline = 0%). This difference was subjected to the t-test. Two-sided P-value is less than or equal to 0.05 and was not adjusted as multiple comparisons were not done.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Assumed placebo-adjusted effect for both active treatment groups (% increase in BMD)was 1.56% and that the placebo adjusted effect for the rsCT tablets must be at least 0.5 times the placebo adjusted effect for the calcitonin nasal spray (active control treatment group). The null hypothesis to be tested was:
[Mean(oral) – Mean(placebo)] - 0.5 x [Mean(nasal) – Mean(placebo)] &lt; 0. Reference Pigeot, et al. 2003</non_inferiority_desc>
            <p_value>0.002</p_value>
            <p_value_desc>The P-value was not adjusted for multiple comparisons. The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.77</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma C-terminal Telopeptide of Collagen 1 (CTx-1)</title>
        <description>Change from baseline in plasma CTx-1 at 24 and 48 weeks. CTx-1 is an accepted plasma biomarker as evidence of an effect on bone resorption and the effect of oral calcitonin was compared to that of intranasal calcitonin, both vs placebo.</description>
        <time_frame>24 weeks</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Calcitonin</title>
            <description>Patients who only received oral calcitonin as an active treatment</description>
          </group>
          <group group_id="O2">
            <title>Nasal Calcitonin</title>
            <description>Patients who only received nasal calcitonin as active treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients who did not receive any active treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma C-terminal Telopeptide of Collagen 1 (CTx-1)</title>
          <description>Change from baseline in plasma CTx-1 at 24 and 48 weeks. CTx-1 is an accepted plasma biomarker as evidence of an effect on bone resorption and the effect of oral calcitonin was compared to that of intranasal calcitonin, both vs placebo.</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>percentage change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.93" spread="41.99"/>
                    <measurement group_id="O2" value="-24.64" spread="41.61"/>
                    <measurement group_id="O3" value="-21.09" spread="62.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Same as for Primary Outcome</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Same as for Primary Outcome</non_inferiority_desc>
            <p_value>0.0006</p_value>
            <p_value_desc>P-value not adjusted for multiple comparisons; a priori threshold for significance was 0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>95% confidence interval not calculated</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-21.84</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>41.99</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma CTx-1 From Baseline</title>
        <description>Percent change from baseline of plasma CTx-1 at end of study=48 weeks</description>
        <time_frame>48 weeks</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Calcitonin</title>
            <description>Patients who only received oral calcitonin as an active treatment</description>
          </group>
          <group group_id="O2">
            <title>Nasal Calcitonin</title>
            <description>Patients who only received nasal calcitonin as active treatment</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients who did not receive any active treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma CTx-1 From Baseline</title>
          <description>Percent change from baseline of plasma CTx-1 at end of study=48 weeks</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>Percentage change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.92" spread="47.53"/>
                    <measurement group_id="O2" value="-11.41" spread="40.24"/>
                    <measurement group_id="O3" value="-11.83" spread="35.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Same as Primary Outcome</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Same as Primary Outcome</non_inferiority_desc>
            <p_value>0.0012</p_value>
            <p_value_desc>p-value not adjusted for multiple comparisons; a priori threshold for statistical significance was set at 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-18.09</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>47.53</dispersion_value>
            <estimate_desc>oral calcitonin vs placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Calcitonin</title>
          <description>Patients who only received oral calcitonin as an active treatment</description>
        </group>
        <group group_id="E2">
          <title>Nasal Calcitonin</title>
          <description>Patients who only received nasal calcitonin as active treatment</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Patients who did not receive any active treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="182"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Cholesystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Facial bone fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Ishaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Bunion operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Cystocele repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Skin lesion excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Therapeutic procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Vaginal operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="182"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="65" subjects_affected="44" subjects_at_risk="263"/>
                <counts group_id="E2" events="51" subjects_affected="29" subjects_at_risk="182"/>
                <counts group_id="E3" events="23" subjects_affected="15" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>abdominal pain upper</sub_title>
                <counts group_id="E1" events="39" subjects_affected="29" subjects_at_risk="263"/>
                <counts group_id="E2" events="28" subjects_affected="18" subjects_at_risk="182"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="32" subjects_at_risk="263"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="182"/>
                <counts group_id="E3" events="11" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="263"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="182"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="263"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="182"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="263"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="263"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="182"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Urinary tract Infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="182"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="263"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="182"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="263"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="182"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="263"/>
                <counts group_id="E2" events="12" subjects_affected="6" subjects_at_risk="182"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="182"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="263"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="182"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Krause, Chief Medical Officer</name_or_title>
      <organization>Tarsa Theapeutics, Inc.</organization>
      <phone>1-267-273-7940</phone>
      <email>dkrause@tarsatherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

